Amgen's AMG420 shows responses in myeloma trial, gets FDA fast track

Amgen Inc, updating the first trial of its bispecific antibody for multiple myeloma, on Monday said seven out of ten patients given the second-highest dose of AMG420 responded to the drug, including four with no detectable cancer.

from Reuters: Health News https://ift.tt/2APJ5Zx
via IFTTT